睿知中国医院研究地图
候选清单

南昌南昌大学

南昌大学第二附属医院

Second Affiliated Hospital of Nanchang University

在本站收录的 61 种疾病中,这家医院列在其中 29 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

南昌大学第二附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma14 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma96 篇牵头论文
  4. 胃癌Stomach cancer57 篇牵头论文
  5. 肺癌Lung cancer105 篇牵头论文牵头 5 项开放试验
  6. 胰腺癌Pancreatic cancer22 篇牵头论文
  7. 乳腺癌Breast cancer19 篇牵头论文
  8. 胶质瘤Glioma60 篇牵头论文
  9. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  10. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  11. 骨肉瘤Osteosarcoma26 篇牵头论文
  12. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  13. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  14. 多发性骨髓瘤Multiple myeloma10 篇牵头论文
  15. 淋巴瘤Lymphoma15 篇牵头论文牵头 1 项开放试验
  16. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  17. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  18. 烟雾病Moyamoya disease3 篇牵头论文
  19. 肝豆状核变性Wilson disease1 篇牵头论文
  20. 冠心病Coronary heart disease21 篇牵头论文
  21. 先天性心脏病Congenital heart disease11 篇牵头论文
  22. 大动脉炎Takayasu arteritis0 篇牵头论文
  23. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  24. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  25. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  26. IgA 肾病IgA nephropathy10 篇牵头论文
  27. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  28. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  29. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、胆道闭锁、脊柱侧弯、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。

牵头论文
14
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 3320242025: 662025

南昌有 3 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    发布
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

  2. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    发布
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术副作用与生活质量诱导/同步化疗
论文中的科室肿瘤内科耳鼻喉/头颈外科风湿免疫科放疗科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. A comparative study of different parameter estimation methods for predictive models of Normal Tissue Complication Probability (NTCP) of radiation-induced temporal lobe injury following intensity-modulated radiotherapy in nasopharyngeal carc2025BMC cancer免费全文
  2. Role of Coiled-Coil Domain-Containing Protein 86 in Tumorigenesis of Nasopharyngeal Carcinoma.2025Bulletin of experimental biology and medicine
  3. Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma.2025European journal of medical research免费全文
  4. ETV5 transcriptionally activates LGR4 and promotes cancer cell invasion and migration of nasopharyngeal carcinoma.2025Journal of molecular histology
  5. ANLN knockdown inhibits nasopharyngeal carcinoma proliferation and is associated with impaired ribosome biogenesis.2025Neoplasma
  6. The NSUN2-YBX1 axis enhances 5-Methylcytosine modification to facilitate NPM1-mediated nuclear translocation of PKM2, augmenting the Warburg effect and promoting nasopharyngeal carcinoma progression in a mouse model.2025Rhinology
  7. A Neural Network-based Method for Predicting Dose to Organs at Risk in Intensity-modulated Radiotherapy for Nasopharyngeal Carcinoma.2024Clinical oncology (Royal College of Radiologists (Great Britain))
  8. Explore the shared molecular mechanism between dermatomyositis and nasopharyngeal cancer by bioinformatic analysis.2024PloS one免费全文
  9. MiR-122-5p regulates erastin-induced ferroptosis via CS in nasopharyngeal carcinoma.2024Scientific reports免费全文
  10. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating EGFR and activating the PI3K/Akt signaling.2023Neoplasma
  11. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  12. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.2022BMJ open免费全文
  13. A Prospective Study on Defining the Indications of Prophylactic Level IB Radiotherapy in Nasopharyngeal Carcinoma Based on a Risk Score Model.2022Oncology research and treatment
  14. Overexpression of HOXA10 promotes the growth and metastasis of nasopharyngeal carcinoma.2021Experimental biology and medicine (Maywood, N.J.)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury状态不明NCT03069820牵头方IV期2017-02 启动
  2. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  3. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy正在招募NCT05892354研究中心不分期2023-06 启动
  4. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  5. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  6. Endostar for Locally Recurrent Nasopharyngeal Carcinoma状态不明NCT02636231研究中心II期2015-11 启动
PubMed 以外找到的论文(未计入)3
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  2. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要
  3. Risk Analysis of Severe Thrombocytopenia in Nasopharyngeal Carcinoma During Concurrent Radio-Chemotherapy2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025

南昌有 3 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    发布
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心十堰、南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能
论文中的科室病理/检验科
牵头的论文4
  1. AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.2025Molecular genetics and genomics : MGG
  2. ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.2025Scientific reports免费全文
  3. Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma.2023Aging免费全文
  4. USP18 promotes tumor metastasis in esophageal squamous cell carcinomas via deubiquitinating ZEB1.2021Experimental cell research
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  2. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  3. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  4. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)3
  1. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncology撤稿
  2. Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  3. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 96 篇,占 0.7%。

牵头论文
96
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 161620222023: 222220232024: 202020242025: 22222025

南昌有 3 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    发布
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  2. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  3. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    发布
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  4. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    发布
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  5. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    发布
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

  6. 即将招募
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    分期
    不分期
    开始
    2026-10
    发布
    登记号
    NCT07596134

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南昌、台州、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科肿瘤内科消化/肝病科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文96
  1. TMEM44 as a Novel Prognostic Marker for Hepatocellular Carcinoma is Associated with Tumor Invasion, Migration, and Apoptosis.2026Biochemical genetics
  2. NCAPG confers ferroptosis resistance of hepatocellular carcinoma through NSUN2-mediated m5C modification.2026Cellular signalling
  3. Diosgenin targets ITGA11-driven angiogenesis in hepatocellular carcinoma: Prognostic and mechanistic insights.2026Computational biology and chemistry
  4. BAG6 promotes hepatocellular carcinoma growth via enhancing PLK1-mediated aerobic glycolysis.2026International journal of biological macromolecules
  5. Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study.2025BMC cancer免费全文
  6. ACSM5 Regulates Ferroptosis in Hepatocellular Carcinoma by Up-Regulating POR and Modulating Lipid Metabolism.2025Cancer science免费全文
  7. SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma.2025Cell death & disease免费全文
  8. NUB1 reduction promotes PCNA-mediated tumor growth by disturbing the PCNA polyubiquitination/NEDDylation in hepatocellular carcinoma cells.2025Cell death & disease免费全文
  9. Elevated P4HB expression in hepatocellular carcinoma and its role in UCA1-mediated malignant progression.2025Cellular signalling
  10. NCAPG promotes epithelial-mesenchymal transition through SIP-dependent ubiquitination regulation of β-catenin in hepatocellular carcinoma.2025Cellular signalling
  11. AHCTF1 Functions as an Oncogenic Factor and Promotes Tumor Progression in Hepatocellular Carcinoma.2025Digestive diseases and sciences免费全文
  12. XPD Regulates MIAT/miR-29a-3p/COL4A1 Axis to Impede Hepatocellular Carcinoma Development.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  13. Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  14. PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1.2025Frontiers in immunology免费全文
  15. DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway.2025Functional & integrative genomics
  16. Rapid detection of plasma exosomal LncRNA CASC9 for HCC using RT-RPA-CRISPR/Cas12a assay.2025Journal of pharmaceutical and biomedical analysis
  17. High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression.2025Journal of translational medicine免费全文
  18. METTL3-mediated TUG1 regulation of miR-9 in doxorubicin resistance in HCC.2025Life sciences
  19. Comprehensive Bioinformatics Analysis and Machine Learning of TTK as a Transhepatic Arterial Chemoembolization Resistance Target in Hepatocellular Carcinoma.2025Molecular biotechnology
  20. Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis.2025Naunyn-Schmiedeberg's archives of pharmacology
  21. Modeling the prediction of spontaneous rupture and bleeding in hepatocellular carcinoma via machine learning algorithms.2025Scientific reports免费全文
  22. The m6A reader IGF2BP3 promotes HCC progression by enhancing MCM10 stability.2025Scientific reports免费全文
  23. hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.2025Scientific reports免费全文
  24. Multiomic characterization, immunological and prognostic potential of SMAD3 in pan-cancer and validation in LIHC.2025Scientific reports免费全文
  25. Comparative efficacy and safety of lenvatinib, sintilimab combined interventional therapy vs bevacizumab, sintilimab combined interventional therapy in intermediate and advanced hepatocellular carcinoma: a multicenter retrospective study.2025World journal of surgical oncology免费全文
  26. A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor.2025World journal of surgical oncology免费全文
  27. Comprehensive prognostic and immunological analysis of Cullin2 in pan-cancer and its identification in hepatocellular carcinoma.2024Aging免费全文
  28. Development of machine learning-based personalized predictive models for risk evaluation of hepatocellular carcinoma in hepatitis B virus-related cirrhosis patients with low levels of serum alpha-fetoprotein.2024Annals of hepatology
  29. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.2024Cancer medicine免费全文
  30. Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.2024Cancer science免费全文
  31. USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma.2024Cell communication and signaling : CCS免费全文
  32. SNRPB2 in the pan-cancer landscape: A bioinformatics exploration and validation in hepatocellular carcinoma.2024Cellular signalling
  33. PSMD11 promotes the proliferation of hepatocellular carcinoma by regulating the ubiquitination degradation of CDK4.2024Cellular signalling
  34. Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR-224/HOXD10 axis.2024Environmental toxicology
  35. Knockdown of circZMIZ1 enhances the anti-tumor activity of CD8+ T cells to alleviate hepatocellular carcinoma.2024Functional & integrative genomics
  36. SRSF7 is a promising prognostic biomarker in hepatocellular carcinoma and is associated with immune infiltration.2024Genes & genomics
  37. The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.2024Journal of advanced research免费全文
  38. Homeobox B9 promotes the invasion and metastasis of hepatocellular carcinoma cells via the EZH2-MIR203A-SNAI2 axis.2024Journal of translational medicine免费全文
  39. AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy.2024Journal of translational medicine免费全文
  40. The HHEX-ABI2/SLC17A9 axis induces cancer stem cell-like properties and tumorigenesis in HCC.2024Journal of translational medicine免费全文
  41. BarH-Like Homeobox 2 Suppresses Cell Proliferation, Invasion, and Angiogenesis in Hepatocellular Carcinoma by Activating N-Acetylgalactosaminyltransferase 4.2024Molecular biotechnology
  42. Hepatic Symbiotic Bacterium L. reuteri FLRE5K1 Inhibits the Development and Progression of Hepatocellular Carcinoma via Activating the IFN-γ/CXCL10/CXCR3 Pathway.2024Probiotics and antimicrobial proteins
  43. Comparative analysis of the safety and feasibility of laparoscopic and open approaches for right anterior sectionectomy.2024Scientific reports免费全文
  44. SNX16 is required for hepatocellular carcinoma survival via modulating the EGFR-AKT signaling pathway.2024Scientific reports免费全文
  45. PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis.2024Technology in cancer research & treatment免费全文
  46. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.2024World journal of surgical oncology免费全文
  47. ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, m6A modification, and drug susceptibility.2023Aging免费全文
  48. FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma.2023Aging免费全文
  49. Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma.2023Aging免费全文
  50. Biological function analysis of ARHGAP39 as an independent prognostic biomarker in hepatocellular carcinoma.2023Aging免费全文
  51. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.2023BMC cancer免费全文
  52. Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection.2023BMC gastroenterology免费全文
  53. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.2023BMC medical genomics免费全文
  54. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.2023Bioscience reports免费全文
  55. Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer.2023Canadian journal of gastroenterology & hepatology免费全文
  56. The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression.2023Cell death & disease免费全文
  57. CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.2023Current oncology (Toronto, Ont.)免费全文
  58. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.2023European journal of medical research免费全文
  59. Validation of a supplementary condition of eighth AJCC staging system for stage II hepatocellular carcinoma.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  60. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  61. Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  62. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  63. Biejia-Ruangan compound and incidence of hepatocellular carcinoma.2023Journal of hepatology
  64. NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression.2023Neoplasma
  65. Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.2023PloS one免费全文
  66. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.2023Scientific reports免费全文
  67. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.2023Scientific reports免费全文
  68. Based on the IWATE criteria: to investigate the influence of different surgical approaches on the perioperative outcomes of hepatectomy.2023Surgical endoscopy
  69. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma.2022Aging免费全文
  70. Desmocollin-2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma via the ERK/c-MYC signaling pathway.2022Aging免费全文
  71. ZNF320 is a hypomethylated prognostic biomarker involved in immune infiltration of hepatocellular carcinoma and associated with cell cycle.2022Aging免费全文
  72. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.2022Bioengineered免费全文
  73. TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma.2022Cancer biology & therapy免费全文
  74. O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease.2022Cells免费全文
  75. MiR-27a-3p targets USP46 to inhibit the cell proliferation of hepatocellular carcinoma.2022Chemical biology & drug design
  76. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.2022Computational and mathematical methods in medicine免费全文
  77. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.2022Disease markers免费全文
  78. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.2022Frontiers in immunology免费全文
  79. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  80. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  81. NCAPG promotes the proliferation of hepatocellular carcinoma through the CKII-dependent regulation of PTEN.2022Journal of translational medicine免费全文
  82. miR-2392 serves as an immunological and prognostic biomarker in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  83. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.2022Molecular cancer免费全文
  84. DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression.2022Scientific reports免费全文
  85. The deubiquitinase OTUD3 stabilizes ACTN4 to drive growth and metastasis of hepatocellular carcinoma.2021Aging免费全文
  86. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.2021BMC cancer免费全文
  87. Modified median hepatic fissure approach for resection of liver tumours located in the angle between the root of the middle and right hepatic veins.2021BMC surgery免费全文
  88. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.2021Bioengineered免费全文
  89. COL4A1, negatively regulated by XPD and miR-29a-3p, promotes cell proliferation, migration, invasion and epithelial-mesenchymal transition in liver cancer cells.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  90. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer.2021Clinical biochemistry
  91. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1.2021Experimental cell research
  92. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.2021Journal of cellular biochemistry
  93. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.2021Journal of cellular physiology
  94. Silencing of ATG4D suppressed proliferation and enhanced cisplatin-induced apoptosis in hepatocellular carcinoma through Akt/Caspase-3 pathway.2021Molecular and cellular biochemistry
  95. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.2021Oncogene
  96. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC状态不明NCT05582278牵头方(推断)II期2021-01 启动
  2. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC即将招募NCT07596134研究中心不分期2026-10 启动
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  6. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  7. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413研究中心2022-09 启动
  8. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  9. Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)状态不明NCT05594927研究中心III期2022-12 启动
  10. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  11. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  12. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  13. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  14. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 57 篇,占 0.6%。

牵头论文
57
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 4420222023: 8820232024: 191920242025: 12122025

南昌有 3 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    发布
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  2. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    发布
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  3. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    发布
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能腹膜转移与晚期免疫与靶向药物
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科肿瘤内科
牵头的论文57
  1. A Network Information-Based Behavior Change Wheel for Populations at High Risk of Developing Gastric Cancer.2026Journal of cancer education : the official journal of the American Association for Cancer Education
  2. The Role of Yes-Associated Protein in Autophagy and Tumor Progression in Gastric Cancer.2026Molecular biotechnology
  3. P2Y2 receptor as a favorable predictor of gastric cancer.2026Tissue & cell
  4. MR Promotes Ferroptosis in Gastric Cancer by Regulating FANCD2 Expression Mediated by m6A Modification.2025Applied biochemistry and biotechnology
  5. Comprehensive analysis of ferroptosis-related long non-coding RNA and its association with tumor progression and ferroptosis in gastric cancer.2025BMC gastroenterology免费全文
  6. Methionine Restriction Exerts Anti-Tumor Immunity via Joint Intervention of T-Bet Palmitoylation in Gastric Cancer.2025Biotechnology journal
  7. Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.2025Cancer letters
  8. HNF4A promotes tumor progression in gastric cancer by transcriptional activation of KIF2C.2025Clinical and experimental medicine免费全文
  9. Skeletal muscle gauge: A superior predictor of neoadjuvant chemoimmunotherapy efficacy in locally advanced gastric cancer.2025Clinical nutrition ESPEN
  10. TFAP4 Regulation of MCM5 Activates the PI3K/AKT Pathway to Promote Invasion and Metastasis of Gastric Cancer.2025Digestive diseases and sciences
  11. ChatGPT-4o outperforms gemini advanced in assisting multidisciplinary decision-making for advanced gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  12. A Golgi apparatus-related signature predicts the immune microenvironment and prognosis of gastric cancer.2025Genes and immunity
  13. P2X7 receptor promotes the growth and metastasis of gastric cancer by activating P13/AKT/GSK-3 beta signaling (experimental research).2025International journal of surgery (London, England)免费全文
  14. The functional role of P2 purinergic receptors in the progression of gastric cancer.2025Purinergic signalling免费全文
  15. Research Progress in Clinical Applications of Gastric Contrast-Enhanced Ultrasound.2025Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  16. Upregulation of E-cadherin by the combination of methionine restriction and HDAC2 intervention for inhibiting gastric carcinoma metastasis.2024Acta biochimica et biophysica Sinica免费全文
  17. Influence of Postoperative Insulin Resistance on Short-Term Outcomes of Radical Gastrectomy for Gastric Cancer: A Microbiome and Metabolome-Based Prospective Cohort Study.2024Annals of surgical oncology
  18. Probiotic Compounds Enhanced Recovery after Surgery for Patients with Distal Gastric Cancer: A Prospective, Controlled Clinical Trial.2024Annals of surgical oncology
  19. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer.2024Apoptosis : an international journal on programmed cell death
  20. Methionine restriction attenuates the migration and invasion of gastric cancer cells by inhibiting nuclear p65 translocation through TRIM47.2024Biological chemistry
  21. Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer.2024Biology direct免费全文
  22. The Role of Methionine Restriction in Gastric Cancer: A Summary of Mechanisms and a Discussion on Tumor Heterogeneity.2024Biomolecules免费全文
  23. Construction of a disulfidptosis-related glycolysis gene risk model to predict the prognosis and immune infiltration analysis of gastric adenocarcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  24. Methionine restriction promotes cisplatin sensitivity of gastric cancer resistant cells by down-regulating circ-CDK13 level.2024Experimental cell research
  25. KLF10/CBS increases the sensitivity of gastric carcinoma cells to methionine restriction by promoting sulfur transfer pathway.2024Experimental cell research
  26. Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy.2024Frontiers in immunology免费全文
  27. Machine learning to predict distant metastasis and prognostic analysis of moderately differentiated gastric adenocarcinoma patients: a novel focus on lymph node indicators.2024Frontiers in immunology免费全文
  28. Exosome as a crucial communicator between tumor microenvironment and gastric cancer (Review).2024International journal of oncology免费全文
  29. Identification roles of NFE2L3 in digestive system cancers.2024Journal of cancer research and clinical oncology免费全文
  30. The relationship between periodontal disease and gastric cancer: A bidirectional Mendelian randomization study.2024Medicine免费全文
  31. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.2024Medicine免费全文
  32. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.2024Medicine免费全文
  33. Development and external validation of a nomogram predicting overall survival for Gastric adenocarcinoma patients with radical gastrectomy.2024Scandinavian journal of gastroenterology
  34. Role of P2X7 receptor in the progression and clinicopathological characteristics of gastric cancer.2024Scientific reports免费全文
  35. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.2023Apoptosis : an international journal on programmed cell death
  36. AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer.2023Carcinogenesis
  37. Landscapes and mechanisms of CD8+ T cell exhaustion in gastrointestinal cancer.2023Frontiers in immunology免费全文
  38. Target tumor therapy in human gastric cancer cells through the combination of docetaxel-loaded cationic lipid microbubbles and ultrasound-triggered microbubble destruction.2023Functional & integrative genomics
  39. SKAP1 Is a Novel Biomarker and Therapeutic Target for Gastric Cancer: Evidence from Expression, Functional, and Bioinformatic Analyses.2023International journal of molecular sciences免费全文
  40. LncRNA POU6F2-AS2 contributes to malignant phenotypes and paclitaxel resistance by promoting SKP2 expression in stomach adenocarcinoma.2023Journal of chemotherapy (Florence, Italy)
  41. Cancer functional states-based molecular subtypes of gastric cancer.2023Journal of translational medicine免费全文
  42. Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer.2023Medicine免费全文
  43. Toll-like receptor 3 is a potential prognosis marker and associated with immune infiltration in stomach adenocarcinoma.2022Cancer biomarkers : section A of Disease markers免费全文
  44. Clostridium butyricum potentially improves inflammation and immunity through alteration of the microbiota and metabolism of gastric cancer patients after gastrectomy.2022Frontiers in immunology免费全文
  45. The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics.2022Frontiers in immunology免费全文
  46. Meta-analysis of the prognostic value of circulating tumor cells in gastrointestinal cancer.2022Medicine免费全文
  47. The circadian clock is associated with prognosis and immune infiltration in stomach adenocarcinoma.2021Aging免费全文
  48. Constructing a new prognostic signature of gastric cancer based on multiple data sets.2021Bioengineered免费全文
  49. Establishment of a prognostic model of four genes in gastric cancer based on multiple data sets.2021Cancer medicine免费全文
  50. USP1 Promotes GC Metastasis via Stabilizing ID2.2021Disease markers免费全文
  51. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer.2021EMBO reports免费全文
  52. Adjuvant treatment and molecular mechanism of probiotic compounds in patients with gastric cancer after gastrectomy.2021Food & functionRCT
  53. Establishment of a prognostic model of ten transcription factors in gastric cancer.2021Genomics
  54. Combining the platelet-to-albumin ratio with serum and pathologic variables to establish a risk assessment model for lymph node metastasis of gastric cancer.2021Journal of biological regulators and homeostatic agents
  55. Long noncoding RNA TUG1 upregulates VEGFA to enhance malignant behaviors in stomach adenocarcinoma by sponging miR-29c-3p.2021Journal of clinical laboratory analysis免费全文
  56. Exosome-mediated transfer of lncRNA HCG18 promotes M2 macrophage polarization in gastric cancer.2021Molecular immunology
  57. Methionine deficiency promoted mitophagy via lncRNA PVT1-mediated promoter demethylation of BNIP3 in gastric cancer.2021The international journal of biochemistry & cell biology
中文论文(未计入)1
  1. [Expression characteristics and functional analysis of ELK3 in gastric cancer].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  2. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  3. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413研究中心2022-09 启动
  4. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  6. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  7. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  8. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  9. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 105 篇,占 0.4%。

牵头论文
105
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
24
由其他机构牵头
每年牵头的论文数
2021: 191920212022: 111120222023: 232320232024: 202020242025: 30302025

南昌有 4 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 29

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
    分期
    不分期
    开始
    2026-02
    发布
    登记号
    NCT07398599

    年龄 18 岁 至 99 岁(登记的条件)

    牵头:南昌大学第二附属医院南昌

  2. 正在招募
    Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
    分期
    I/II期
    开始
    2026-07
    发布
    登记号
    NCT07655622

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南昌大学第二附属医院南昌

  3. 正在招募
    SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
    分期
    II/III期
    开始
    2025-04
    发布
    登记号
    NCT07131319

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:南昌大学第二附属医院南昌

  4. 正在招募
    Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
    分期
    II期
    开始
    2024-07
    发布
    登记号
    NCT06554613

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南昌大学第二附属医院南昌

  5. 邀请入组
    Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06773156

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南昌大学第二附属医院南昌

  6. 正在招募
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2026-01
    发布
    登记号
    NCT07222566

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、台州、合肥、太原、广州、成都、扬州、新乡、杭州、武汉、江门、洛阳、济南、温州、福州、襄阳、郑州、重庆、长春、长沙

  7. 正在招募
    A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
    分期
    III期
    开始
    2026-03
    发布
    登记号
    NCT07361497

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心北京、南昌、台州、太原、广州、成都、杭州、汕头、济南、深圳、福州、苏州、西安、郑州、重庆

  8. 正在招募
    A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
    分期
    III期
    开始
    2026-03
    发布
    登记号
    NCT07361510

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、南宁、南昌、广州、成都、杭州、汕头、济南、福州

  9. 正在招募
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07472517

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、哈尔滨、天津、太原、宁波、广州、徐州、成都、扬州、杭州、武汉、济南、温州、福州、蚌埠、襄阳、郑州、长沙

  10. 正在招募
    A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2026-10
    发布
    登记号
    NCT07541170

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心佛山、北京、南昌、台州、合肥、天津、广州、成都、杭州、济南、深圳、苏州、长春

  11. 正在招募
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06801834

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、临沂、北京、南京、南昌、厦门、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、深圳、福州、西安、郑州、重庆、长春

  12. 正在招募
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06875310

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、汕头、沈阳、济南、深圳、石家庄、福州、苏州、蚌埠、重庆、长春、长沙

  13. 正在招募
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    分期
    I/II期
    开始
    2025-05
    发布
    登记号
    NCT06892548

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心临沂、北京、南京、南宁、南昌、厦门、合肥、宜昌、广州、徐州、成都、新乡、杭州、济南、福州、襄阳、西安、郑州、长春

  14. 正在招募
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    分期
    III期
    开始
    2025-10
    发布
    登记号
    NCT06899126

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南昌、合肥、哈尔滨、天津、太原、广州、成都、杭州、武汉、沈阳、济南、襄阳、郑州、重庆、长春、长沙

  15. 正在招募
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    分期
    I/II期
    开始
    2025-09
    发布
    登记号
    NCT07111520

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、南昌、合肥、天津、广州、徐州、成都、扬州、新乡、武汉、济南、石家庄、福州、苏州、襄阳、重庆、长春、青岛

  16. 正在招募
    IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    分期
    II期
    开始
    2025-11
    发布
    登记号
    NCT07198841

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心佛山、北京、南宁、南昌、广州、石家庄

  17. 正在招募
    PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
    分期
    未注明
    开始
    2025-10
    发布
    登记号
    NCT07775820

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院;另有 4 家列出的医院为研究中心南昌、广州、深圳、温州

  18. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    发布
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、武汉、洛阳、福州、西安、郑州、重庆

  19. 正在招募
    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
    分期
    I期
    开始
    2024-01
    发布
    登记号
    NCT06179069

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、广州、成都、武汉、沈阳、西安、郑州、长沙

  20. 正在招募
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06203210

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、哈尔滨、天津、成都、杭州、武汉、沈阳、济南、烟台、襄阳、郑州、重庆、长沙

  21. 正在招募
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06345729

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙

  22. 正在招募
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    分期
    III期
    开始
    2024-06
    发布
    登记号
    NCT06422143

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、台州、哈尔滨、广州、成都、扬州、杭州、武汉、温州、福州、郑州、长春、长沙

  23. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    发布
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  24. 正在招募
    DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
    分期
    II期
    开始
    2023-10
    发布
    登记号
    NCT05882058

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、南昌、成都、杭州、济南

  25. 正在招募
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT06095583

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、武汉、沈阳、济南、深圳、郑州、重庆、银川、长春、长沙、青岛

  26. 正在招募
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06170788

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙

  27. 正在招募
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2022-03
    发布
    登记号
    NCT04928846

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙

  28. 即将招募
    A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
    分期
    III期
    开始
    2026-10
    发布
    登记号
    NCT07833202

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心南昌

  29. 即将招募
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    分期
    III期
    开始
    2023-05
    发布
    登记号
    NCT05767892

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、北京、南京、南昌、厦门、台州、合肥、呼和浩特、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科影像/核医学科普外/肝胆胰外科
牵头的论文105
  1. SLBP promotes lung adenocarcinoma progression by inhibiting ferroptosis and reprogramming glutamine metabolism via FADS2 interaction.2026Experimental cell research
  2. Per- and polyfluoroalkyl substances induce cytotoxicity in NCI-H446 cells through modulating proliferation, apoptosis, and m6A methylation.2026Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  3. Development and validation of nomogram for predicting the cancer-specific survival among patients aged 80 and above with early-stage non-small cell lung cancer.2025ANZ journal of surgery
  4. Dual-energy CT Radiomics Combined with Quantitative Parameters for Differentiating Lung Adenocarcinoma From Squamous Cell Carcinoma: A Dual-center Study.2025Academic radiology
  5. Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.2025BMC cancer免费全文
  6. The added value of quantitative contrast-enhanced CT parameters in distinguishing malignant from benign solid pulmonary nodules.2025BMC medical imaging免费全文
  7. Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.2025Cancer
  8. Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.2025Cancer immunology, immunotherapy : CII免费全文
  9. Opportunities and challenges for non-small cell lung cancer brain metastases in the immunotherapy era.2025Cancer treatment reviews
  10. Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer.2025Cell communication and signaling : CCS免费全文
  11. Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  12. GBP2 regulates lung cancer progression through STAT1 and impacts glycolysis.2025Clinical and experimental medicine免费全文
  13. Identification and external validation of a prognostic signature based on MAPK-related genes to evaluate survival prognosis and treatment efficacy in lung adenocarcinoma.2025Clinical and experimental medicine免费全文
  14. Innovative technologies and their clinical prospects for early lung cancer screening.2025Clinical and experimental medicine免费全文
  15. Cancer-associated Fibroblasts (CAFs) Regulate Lung Cancer Malignant Progression by Transferring SERPINE2 (PN1) via Exosomes.2025Current molecular medicine
  16. Decoding the role of lipid metabolism in NSCLC: From macrophage subtype identification to prognostic model development.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  17. The association between triglyceride glucose-body mass index and overall survival in postoperative patient with lung cancer.2025Frontiers in endocrinology免费全文
  18. PSMD14 drives lung adenocarcinoma progression through HMMR stabilization and dual activation of TGF-β/Smad and PI3K/AKT/mTOR signaling.2025Frontiers in immunology免费全文
  19. Integrative multi-omics reveals energy metabolism-related prognostic signatures and immunogenetic landscapes in lung adenocarcinoma.2025Frontiers in immunology免费全文
  20. Progress in lung cancer study coupled with cognitive frailty in elderly individuals.2025Geriatric nursing (New York, N.Y.)
  21. Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  22. Unraveling molecular characteristics and functional exploration of panoptosis for prognosis stratification in lung adenocarcinoma: a tumor marker prognostic study.2025International journal of surgery (London, England)免费全文
  23. Bidirectional mendelian randomization and single-cell sequencing reveal T cell-mediated causal links between COPD and lung adenocarcinoma.2025International journal of surgery (London, England)
  24. Assessing the Therapeutic Value of Primary Tumor Resection in Colorectal Cancer Lung Metastases: A Dynamic Visualization Clinical Tool Constructed Based on the SEER Database.2025Journal of gastroenterology and hepatology
  25. Integrated multi-omics reveals glycolytic gene signatures of lung adenocarcinoma brain metastasis and the impact of Rac2 lactylation on immunosuppressive microenvironment.2025Journal of translational medicine免费全文
  26. Circ_0002638 drives squamous cell lung cancer (LUSC) progression and chemotherapy resistance by inhibiting ferroptosis via SENP1-mediated deSUMOylation of ACSL4.2025Life sciences
  27. Intrathecal Pemetrexed Administration and Myelosuppression in Patients with Leptomeningeal Metastases from Lung Adenocarcinoma: A Retrospective Study.2025Oncology research免费全文
  28. P21 activated kinase 6: a promising tool for predicting small cell lung cancer diagnosis and treatment response.2025PeerJ免费全文
  29. Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification.2025Scientific reports免费全文
  30. FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation.2025The Journal of biological chemistry免费全文
  31. Primary tumor resection: a new hope or an old illusion for patients with metastatic non-small cell lung neuroendocrine tumors?2025World journal of surgical oncology免费全文
  32. Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis.2025World journal of surgical oncology免费全文
  33. Upregulation of E-cadherin by the combination of methionine restriction and HDAC2 intervention for inhibiting gastric carcinoma metastasis.2024Acta biochimica et biophysica Sinica免费全文
  34. Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage.2024Acta biomaterialia
  35. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.2024Aging免费全文
  36. Machine learning predictive models and risk factors for lymph node metastasis in non-small cell lung cancer.2024BMC pulmonary medicine免费全文
  37. Abnormal expression of LCA and CD43 in SCLC: a rare case report and brief literature review.2024BMC pulmonary medicine免费全文
  38. KLF10/CBS increases the sensitivity of gastric carcinoma cells to methionine restriction by promoting sulfur transfer pathway.2024Experimental cell research
  39. Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma.2024Frontiers in immunology免费全文
  40. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.2024International journal of cancer
  41. Vitamin D-mediated tsRNA-07804 triggers mitochondrial dysfunction and suppresses non-small cell lung cancer progression by targeting CRKL.2024Journal of cancer research and clinical oncology免费全文
  42. Comparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimens or chemotherapy: A study based on the SEER database and multicentric real-world settings.2024Journal of cancer research and therapeutics
  43. Early death incidence and prediction in stage IV large cell neuroendocrine carcinoma of the lung.2024Medicine免费全文
  44. A practical nomogram for predicting early death in elderly small cell lung cancer patients: A SEER-based study.2024Medicine免费全文
  45. Clinical features and prognostic factors of IV combined small cell lung cancer: A propensity score matching analysis.2024PloS one免费全文
  46. Treatment strategies for stage IA non-small cell lung cancer: A SEER-based population study.2024PloS one免费全文
  47. Identification of effective diagnostic genes and immune cell infiltration characteristics in small cell lung cancer by integrating bioinformatics analysis and machine learning algorithms.2024Saudi medical journal免费全文
  48. Douyin and Bilibili as sources of information on lung cancer in China through assessment and analysis of the content and quality.2024Scientific reports免费全文
  49. Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.2024Scientific reports免费全文
  50. Effects of preoperative needle biopsy for lung cancer on survival and recurrence: a systematic review and meta-analysis.2024Surgery today
  51. Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China.2024The Journal of international medical research免费全文
  52. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in lung adenocarcinoma.2024The journal of gene medicine
  53. Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China.2023BMC cancer免费全文
  54. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.2023BMC cancer免费全文
  55. ERCC6 plays a promoting role in the progression of non-small cell lung cancer.2023Biochemistry and cell biology = Biochimie et biologie cellulaire
  56. Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy.2023Biochimica et biophysica acta. Reviews on cancer
  57. Circular RNA hsa_circ_0004689 (circSWT1) promotes NSCLC progression via the miR-370-3p/SNAIL axis by inducing cell epithelial-mesenchymal transition (EMT).2023Cancer medicine免费全文
  58. Circulating hsa_circ_0072309, acting via the miR-100/ACKR3 pathway, maybe a potential biomarker for the diagnosis, prognosis, and treatment of brain metastasis from non-small-cell lung cancer.2023Cancer medicine免费全文
  59. TTI1 promotes non-small-cell lung cancer progression by regulating the mTOR signaling pathway.2023Cancer science免费全文
  60. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.2023Cell death & disease免费全文
  61. Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress.2023Critical reviews in oncology/hematology
  62. Efficacy of PD-1 Inhibitors Combined with Anti-Angiogenic Therapy in Driver Gene Mutation Negative Non-Small-Cell Lung Cancer with Brain Metastases.2023Discovery medicine
  63. The value of serum TRAP1 in diagnosing small cell lung cancer and tumor immunity.2023Experimental biology and medicine (Maywood, N.J.)免费全文
  64. Immune Checkpoint Inhibitors and Tuberculosis Infection in Lung Cancer: A Case Series and Systematic Review With Pooled Analysis.2023Journal of clinical pharmacology
  65. D-D and PLR, NLR combined forecasting first-line treatment: The short-term curative effect and prognosis of patients with SCLC.2023Medicine免费全文
  66. The influence of different sequences of vessel ligation on long-term survival during video-assisted thoracoscopic lobectomy for non-small cell lung cancer: A matched cohort study.2023Medicine免费全文
  67. Competing risk analysis of cardiovascular-specific mortality in typical carcinoid neoplasms of the lung: A SEER database analysis.2023Medicine免费全文
  68. Prognostic value of lymph node ratio in stage III non-small-cell lung cancer: A retrospective cohort study.2023Medicine免费全文
  69. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.2023Medicine免费全文
  70. Pulmonary function protection by single-port thoracoscopic segmental lung resection in elderly patients with IA non-small cell lung cancer: A differential matched analysis.2023Medicine免费全文
  71. Five-hub genes identify potential mechanisms for the progression of asthma to lung cancer.2023Medicine免费全文
  72. Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study.2023Medicine免费全文
  73. Uniportal versus multiportal video-assisted thoracoscopic segmentectomy for non-small cell lung cancer: a systematic review and meta-analysis.2023Surgery today
  74. Comparative analysis of methodologies for predicting overall survival in patients with non-small cell lung cancer based on the number and rate of resected positive lymph nodes: A study based on the SEER database for 2010 through 2019.2023The clinical respiratory journal免费全文
  75. Surgery for stage IIB-IIIB small cell lung cancer.2023World journal of surgical oncology免费全文
  76. TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.2022Asia-Pacific journal of clinical oncology
  77. Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.2022BMC cancer免费全文
  78. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.2022BMC cancer免费全文
  79. PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model.2022International immunopharmacology
  80. CircRPPH1 promotes cell proliferation, migration and invasion of non-small cell lung cancer via the PI3K/AKT and JAK2/STAT3 signalling axes.2022Journal of biochemistry
  81. Application of collagen triple helix repeat containing-1 and mitotic spindle apparatus antibody in small cell lung cancer diagnosis.2022Journal of clinical laboratory analysis免费全文
  82. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.2022Journal of clinical pharmacy and therapeutics
  83. Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.2022Journal of translational medicine免费全文
  84. Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study.2022MedicineRCT免费全文
  85. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.2022Medicine免费全文
  86. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis.2022Molecular cancer免费全文
  87. DNA methylation of ARHGAP30 is negatively associated with ARHGAP30 expression in lung adenocarcinoma, which reduces tumor immunity and is detrimental to patient survival.2021Aging免费全文
  88. Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and me2021Annals of palliative medicine
  89. Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials.2021Annals of palliative medicine
  90. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.2021BMC cancer免费全文
  91. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.2021BMC cancer免费全文
  92. Potential Role of GST-π in Lung Cancer Stem Cell Cisplatin Resistance.2021BioMed research international免费全文
  93. Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2021Chemotherapy
  94. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.2021Current problems in cancer
  95. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.2021Journal of clinical pharmacy and therapeutics
  96. Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.2021Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  97. Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.2021Lung cancer (Amsterdam, Netherlands)
  98. Heat shock protein B8 promotes proliferation and migration in lung adenocarcinoma A549 cells by maintaining mitochondrial function.2021Molecular and cellular biochemistry
  99. Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC.2021Molecular cancer免费全文
  100. Overview of serpin B9 and its roles in cancer (Review).2021Oncology reports
  101. Role of hypoxia‑inducible factor‑2α in lung cancer (Review).2021Oncology reports
  102. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.2021Pharmacological research
  103. Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database.2021Radiation oncology (London, England)免费全文
  104. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.2021Thoracic cancer免费全文
  105. The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)59
  1. Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression正在招募NCT07655622牵头方I/II期2026-07 启动
  2. Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study正在招募NCT07398599牵头方不分期2026-02 启动
  3. SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC正在招募NCT07131319牵头方II/III期2025-04 启动
  4. Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer邀请入组NCT06773156牵头方II期2024-11 启动
  5. Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC正在招募NCT06554613牵头方II期2024-07 启动
  6. Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis状态不明NCT04944069牵头方不分期2021-07 启动
  7. Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib状态不明NCT04358562牵头方II期2020-05 启动
  8. The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC状态不明NCT04193007牵头方II期2019-12 启动
  9. Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer状态不明NCT04425681牵头方II期2017-10 启动
  10. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)正在招募NCT07361497研究中心III期2026-03 启动
  11. A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)正在招募NCT07361510研究中心III期2026-03 启动
  12. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy正在招募NCT07472517研究中心III期2026-04 启动
  13. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer正在招募NCT07222566研究中心III期2026-01 启动
  14. A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation即将招募NCT07833202研究中心III期2026-10 启动
  15. A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)正在招募NCT07541170研究中心III期2026-10 启动
  16. Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer正在招募NCT06801834研究中心III期2025-04 启动
  17. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)正在招募NCT06875310研究中心III期2025-04 启动
  18. IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation正在招募NCT07198841研究中心II期2025-11 启动
  19. A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer正在招募NCT06892548研究中心I/II期2025-05 启动
  20. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer正在招募NCT06899126研究中心III期2025-10 启动
  21. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)正在招募NCT07111520研究中心I/II期2025-09 启动
  22. PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer正在招募NCT07775820研究中心2025-10 启动
  23. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer正在招募NCT06203210研究中心III期2024-05 启动
  24. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  25. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)正在招募NCT06345729研究中心III期2024-05 启动
  26. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  27. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]正在招募NCT06422143研究中心III期2024-06 启动
  28. A Study of ZL-1310 in Subjects With Small Cell Lung Cancer正在招募NCT06179069研究中心I期2024-01 启动
  29. DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers正在招募NCT05882058研究中心II期2023-10 启动
  30. Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)正在招募NCT06095583研究中心III期2023-11 启动
  31. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations即将招募NCT05767892研究中心III期2023-05 启动
  32. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)正在招募NCT06170788研究中心III期2023-12 启动
  33. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)正在招募NCT04928846研究中心III期2022-03 启动
  34. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)进行中,不再招募NCT06305754研究中心III期2024-06 启动
  35. A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer已终止NCT06685718研究中心I期2024-12 启动
  36. ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors进行中,不再招募NCT05671510研究中心III期2023-06 启动
  37. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)进行中,不再招募NCT06074588研究中心III期2023-11 启动
  38. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)进行中,不再招募NCT05609968研究中心III期2023-02 启动
  39. Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)已终止NCT05226598研究中心III期2022-03 启动
  40. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  41. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)进行中,不再招募NCT05668988研究中心III期2022-12 启动
  42. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer状态不明NCT05042375研究中心III期2022-09 启动
  43. A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer进行中,不再招募NCT05297890研究中心II期2022-05 启动
  44. Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT05502237研究中心III期2022-10 启动
  45. Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC已完成NCT04768075研究中心III期2021-05 启动
  46. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer已终止NCT04921358研究中心III期2021-07 启动
  47. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)进行中,不再招募NCT05712902研究中心II期2021-07 启动
  48. Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)进行中,不再招募NCT04380636研究中心III期2020-07 启动
  49. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China已完成NCT04830826研究中心2020-07 启动
  50. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer已完成NCT04205812研究中心III期2020-09 启动
  51. Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)进行中,不再招募NCT04624204研究中心III期2020-12 启动
  52. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)进行中,不再招募NCT03974022研究中心I/II期2019-07 启动
  53. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer已终止NCT03516084研究中心III期2018-08 启动
  54. A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)进行中,不再招募NCT03178552研究中心II/III期2017-09 启动
  55. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China已完成NCT03059641研究中心2017-02 启动
  56. PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients状态不明NCT03029858研究中心2017-01 启动
  57. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT04237805研究中心I/II期2016-11 启动
  58. Afatinib in NSCLC With HER2 Mutation已完成NCT02597946研究中心II期2016-03 启动
  59. Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)已完成NCT02388919研究中心II/III期2015-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.4%。

牵头论文
22
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 7720232024: 4420242025: 552025

南昌有 3 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    发布
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科病理/检验科消化/肝病科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文22
  1. The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability.2025Cell death & disease免费全文
  2. Prognostic differential subpopulation classification and immunotherapy response prediction in pancreatic cancer patients based on the gene features of necrotizing apoptosis.2025Frontiers in immunology免费全文
  3. KIFC1 Overexpression Promotes Pancreatic Carcinoma Progression via Stabilising BUB1B.2025Journal of cellular and molecular medicine免费全文
  4. Application of pancreaticojejunostomy without suturing main pancreatic duct in laparoscopic pancreaticoduodenectomy for small main pancreatic duct (≤ 3 mm).2025Langenbeck's archives of surgery免费全文
  5. Bioinformatics analysis identifies NT5M modulates immune evasion through PD-L1 via CXCL8 in pancreatic adenocarcinoma.2025Scientific reports免费全文
  6. Identification of STAM-binding protein as a target for the treatment of gemcitabine resistance pancreatic cancer in a nutrient-poor microenvironment.2024Cell death & disease免费全文
  7. HKDC1 promotes autophagy and proliferation in pancreatic adenocarcinoma through interaction with PARP1 and poly(ADP-ribosyl)ation.2024Cellular signalling
  8. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.2024Molecular cancer therapeutics
  9. PAFAH1B3 is a KLF9 target gene that promotes proliferation and metastasis in pancreatic cancer.2024Scientific reports免费全文
  10. MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2.2023Aging免费全文
  11. Pancreatic adenosquamous carcinoma: A population level analysis of epidemiological trends and prognosis.2023Cancer medicine免费全文
  12. FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.2023Digestive diseases and sciences
  13. Epidemiological trends for functional pancreatic neuroendocrine tumors: A study combining multiple imputation with age adjustment.2023Frontiers in endocrinology免费全文
  14. Pan-cancer analysis of Krüppel-like factor 3 and its carcinogenesis in pancreatic cancer.2023Frontiers in immunology免费全文
  15. Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.2023Frontiers in immunology免费全文
  16. SLC35F2-SYVN1-TRIM59 axis critically regulates ferroptosis of pancreatic cancer cells by inhibiting endogenous p53.2023Oncogene
  17. FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.2022Cell death & disease免费全文
  18. Comprehensive analysis of the effects of KIF2C on prognosis, biological functions and immune infiltration in PAAD.2022Tissue & cell
  19. USP28 facilitates pancreatic cancer progression through activation of Wnt/β-catenin pathway via stabilising FOXM1.2021Cell death & disease免费全文
  20. E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1.2021Journal of translational medicine免费全文
  21. Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation.2021Oncogene
  22. E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα.2021Oncogene
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413研究中心2022-09 启动
  2. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  3. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.1%。

牵头论文
19
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 5520222023: 4420232024: 4420242025: 332025

南昌有 4 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    分期
    III期
    开始
    2023-06
    发布
    登记号
    NCT05646862

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心南京、南昌、天津、广州、成都、杭州、武汉、济南、重庆、长春

  2. 正在招募
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    分期
    III期
    开始
    2023-09
    发布
    登记号
    NCT05894239

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南宁、南昌、天津、成都、杭州、武汉、洛阳、济南、石家庄、福州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科消化/肝病科肿瘤内科病理/检验科
牵头的论文19
  1. circSCYL2 antagonizes hnRNPA2B1-mediated m6A-chromatin crosstalk to promote ferroptosis and inhibit metastasis of breast cancer to brain.2026International journal of biological macromolecules
  2. Efficacy of fulvestrant and capecitabine as maintenance therapy in patients with HR +/HER2 - metastatic breast cancer benefited from first-line chemotherapy.2026Naunyn-Schmiedeberg's archives of pharmacology
  3. Mapping Knowledge Landscapes and Emerging Trends in Contrast-Enhanced Ultrasound for Breast Cancer: A Bibliometric and Visualization Analysis.2026Ultrasound in medicine & biology
  4. Network pharmacology and in vitro analyses reveal EGCG inhibits breast cancer progression via suppression of the EGFR/Src pathway.2025Biochemical and biophysical research communications
  5. ATP ion channel-type P2X purinergic receptors as a key regulatory molecule in breast cancer progression.2025Pathology, research and practice
  6. Molecular Subtypes and Radiotherapy as Determinants of Survival in Invasive Breast Cancer: Insights from a Single-Center Study.2025Southern medical journal
  7. Predicting efficacy of neoadjuvant chemotherapy in breast cancer patients with synthetic magnetic resonance imaging method MAGiC: An observational cohort study.2024European journal of radiology
  8. Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer.2024European journal of radiology
  9. Butyrate inhibits the malignant biological behaviors of breast cancer cells by facilitating cuproptosis-associated gene expression.2024Journal of cancer research and clinical oncology免费全文
  10. Exploring the interplay between triple-negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies.2024Journal of cellular physiology
  11. PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials.2023Cancer chemotherapy and pharmacology
  12. Prediction of sentinel lymph node metastasis in breast cancer by using deep learning radiomics based on ultrasound images.2023Medicine免费全文
  13. Ferroptosis-dependent breast cancer cell-derived exosomes inhibit migration and invasion of breast cancer cells by suppressing M2 macrophage polarization.2023PeerJ免费全文
  14. Membrane metalloendopeptidase (MME) is positively correlated with systemic lupus erythematosus and may inhibit the occurrence of breast cancer.2023PloS one免费全文
  15. E3 ubiquitin ligase RBX1 drives the metastasis of triple negative breast cancer through a FBXO45-TWIST1-dependent degradation mechanism.2022Aging免费全文
  16. RAMP2-AS1 inhibits CXCL11 expression to suppress malignant phenotype of breast cancer by recruiting DNMT1 and DNMT3B.2022Experimental cell research
  17. Trait emotional intelligence and quality of life among breast cancer patients: The mediating role of fear of cancer recurrence.2022International journal of nursing practice
  18. Circ_0000442 functions as a tumor repressor in breast cancer by impacting miR-1229-3p and upregulating ZBTB1.2022Mammalian genome : official journal of the International Mammalian Genome Society
  19. A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors.2022Scientific reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy正在招募NCT05646862研究中心III期2023-06 启动
  2. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer正在招募NCT05894239研究中心III期2023-09 启动
  3. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer进行中,不再招募NCT05132582研究中心III期2022-03 启动
  4. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer已完成NCT03084237研究中心III期2016-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 60 篇,占 0.9%。

牵头论文
60
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 121220222023: 171720232024: 141420242025: 662025

南昌有 3 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。

这些数字背后的记录
论文中的科室神经外科影像/核医学科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文60
  1. FBXL16 regulates TAMs recruitment by mediating cytokine release in gliomas.2025Cancer genetics
  2. STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma.2025Developmental cell
  3. Comprehensive multi-omics approach reveals critical genes and immunometabolic networks in glioblastoma.2025International journal of surgery (London, England)
  4. Vincristine exerts antiglioma effects by inhibiting the PI3K/AKT signaling pathway: A mechanistic study based on network pharmacology, bioinformatics analysis, and experimental validation.2025Naunyn-Schmiedeberg's archives of pharmacology
  5. WDR4 promotes glioma progression by regulating cell proliferation and cell cycle via the PI3K/Akt-CDK1/2 signaling pathway.2025Neoplasma
  6. TENT5A Increases Glioma Malignancy and Promotes its Progression.2025Recent patents on anti-cancer drug discovery
  7. Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification.2024Aging免费全文
  8. TBC1D1 represses glioma progression by altering the integrity of the cytoskeleton.2024Aging免费全文
  9. Hypoxia conduces the glioma progression by inducing M2 macrophage polarization via elevating TNFSF9 level in a histone-lactylation-dependent manner.2024American journal of physiology. Cell physiology
  10. Decapping enzyme 2 is a novel immune-related biomarker that predicts poor prognosis in glioma.2024Biotechnology & genetic engineering reviews
  11. Identification of Brain Cell Type-Specific Therapeutic Targets for Glioma From Genetics.2024CNS neuroscience & therapeutics免费全文
  12. CIA-II is associated with lower-grade glioma survival and cell proliferation.2024CNS neuroscience & therapeutics免费全文
  13. ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis.2024Cancer chemotherapy and pharmacology
  14. RUNX1-PDIA5 Axis Promotes Malignant Progression of Glioblastoma by Regulating CCAR1 Protein Expression.2024International journal of biological sciences免费全文
  15. Positive feedback loop of c-myc/XTP6/NDH2/NF-κB to promote malignant progression in glioblastoma.2024Journal of experimental & clinical cancer research : CR免费全文
  16. FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs).2024Journal of translational medicine免费全文
  17. The roles of extracellular vesicles in gliomas: Challenge or opportunity?2024Life sciences
  18. PSMB2 plays an oncogenic role in glioma and correlates to the immune microenvironment.2024Scientific reports免费全文
  19. Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy.2024Theranostics免费全文
  20. Exosomal HMGB3 released by glioma cells confers the activation of NLRP3 inflammasome and pyroptosis in tumor-associated macrophages.2024Tissue & cell
  21. The HNF4A-CHPF pathway promotes proliferation and invasion through interactions with MAD1L1 in glioma.2023Aging免费全文
  22. Identified RP2 as a prognostic biomarker for glioma, facilitating glioma pathogenesis mainly via regulating tumor immunity.2023Aging免费全文
  23. SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis.2023Aging免费全文
  24. MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma.2023Aging免费全文
  25. DUSP10 is a novel immune-related biomarker connected with survival and cellular proliferation in lower-grade glioma.2023Aging免费全文
  26. MGME1 associates with poor prognosis and is vital for cell proliferation in lower-grade glioma.2023Aging免费全文
  27. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.2023BMC cancer免费全文
  28. miR-491-5p regulates the susceptibility of glioblastoma to ferroptosis through TP53.2023Biochemical and biophysical research communications
  29. N6-methyladenosine (m6A)-connected lncRNAs are linked to survival and immune infiltration in glioma patients.2023Bioscience reports免费全文
  30. PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.2023Bioscience reports免费全文
  31. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas.2023Cancer medicine免费全文
  32. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.2023Current pharmaceutical design
  33. RPS14 promotes the development and progression of glioma via p53 signaling pathway.2023Experimental cell research
  34. The role of lysosomal peptidases in glioma immune escape: underlying mechanisms and therapeutic strategies.2023Frontiers in immunology免费全文
  35. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies.2023Frontiers in immunology免费全文
  36. Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy.2023Journal of experimental & clinical cancer research : CR免费全文
  37. Identification of a robust scoring system based on metabolic genes followed by in-depth validation of ATP1A3 in glioma.2023Life sciences
  38. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma.2022Aging免费全文
  39. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.2022BMC cancer免费全文
  40. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.2022Bioscience reports免费全文
  41. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.2022Cancer medicine免费全文
  42. Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells In Vitro by Inhibiting Autophagy.2022Computational intelligence and neuroscience免费全文
  43. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.2022Frontiers in immunology免费全文
  44. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.2022Frontiers in immunology免费全文
  45. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.2022Frontiers in immunology免费全文
  46. Radiomics features based on T2-weighted fluid-attenuated inversion recovery MRI predict the expression levels of CD44 and CD133 in lower grade gliomas.2022Future oncology (London, England)
  47. The clinical characteristics and prognostic value of IGFBP6 in glioma.2022Neurological research
  48. Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity.2022Oxidative medicine and cellular longevity免费全文
  49. Suprasellar Ganglioglioma Arising from the Third Ventricle Floor: A Case Report and Review of the Literature.2022Tomography (Ann Arbor, Mich.)免费全文
  50. A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma.2021Aging免费全文
  51. Evaluation of gliomas peritumoral diffusion and prediction of IDH1 mutation by IVIM-DWI.2021Aging免费全文
  52. Exosomes derived from microRNA-512-5p-transfected bone mesenchymal stem cells inhibit glioblastoma progression by targeting JAG1.2021Aging免费全文
  53. TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma.2021Biochemical and biophysical research communications
  54. Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma.2021Bioengineered免费全文
  55. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma.2021Bioengineered免费全文
  56. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.2021Bioscience reports免费全文
  57. Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma.2021Brain research bulletin
  58. Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.2021Frontiers in immunology免费全文
  59. Development of a prognostic index based on immunogenomic landscape analysis in glioma.2021Immunity, inflammation and disease免费全文
  60. Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis.2021Journal of neuro-oncology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Combing a Deep Learning-Based Radiomics With Liquid Biopsy for Preoperative and Non-invasive Diagnosis of Glioma已完成NCT05536024牵头方2022-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南昌有 2 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

南昌有 8 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 26 篇,占 1.1%。

牵头论文
26
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 4420232024: 111120242025: 552025

南昌有 7 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文26
  1. Reversal of MPPa-PDT Resistance in Osteosarcoma by Targeting ROCK2-Mediated Autophagy.2026Cell proliferation免费全文
  2. Silencing Livin gene expression by RNA interference enhanced the chemotherapeutic sensitivity of drug-resistant osteosarcoma cells to doxorubicin.2025Acta histochemica
  3. Identification and functional characterization of T-cell exhaustion-associated lncRNA AL031775.1 in osteosarcoma: a novel therapeutic target.2025Frontiers in immunology免费全文
  4. ACSL4 accelerates osteosarcoma progression via modulating TGF-β/Smad2 signaling pathway.2025Molecular and cellular biochemistry免费全文
  5. Downregulation of ferroptosis-related Genes can regulate the invasion and migration of osteosarcoma cells.2025Scientific reports免费全文
  6. Long non-coding RNA AC133552.2: biomarker and therapeutic target in osteosarcoma via PANoptosis gene screening.2025Scientific reports免费全文
  7. Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma.2024Aging免费全文
  8. Molecular characterization of Golgi apparatus-related genes indicates prognosis and immune infiltration in osteosarcoma.2024Aging免费全文
  9. LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.2024BMC cancer免费全文
  10. The role of programmed cell death in osteosarcoma: From pathogenesis to therapy.2024Cancer medicine免费全文
  11. New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing.2024Cell communication and signaling : CCS免费全文
  12. Curcumin suppresses metastasis, invasion, and proliferation in osteosarcoma cells by regulating the EGFR/Src signaling axis.2024International journal of immunopathology and pharmacology免费全文
  13. USP22 Promotes Osteosarcoma Progression by Stabilising β-Catenin and Upregulating HK2 and Glycolysis.2024Journal of cellular and molecular medicine免费全文
  14. The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma.2024Journal of orthopaedic surgery and research免费全文
  15. Hydroxysafflor yellow A induced ferroptosis of Osteosarcoma cancer cells by HIF-1α/HK2 and SLC7A11 pathway.2024Oncology research免费全文
  16. USP22 as a key regulator of glycolysis pathway in osteosarcoma: insights from bioinformatics and experimental approaches.2024PeerJ免费全文
  17. Development and validation of a novel endoplasmic reticulum stress-related lncRNAs signature in osteosarcoma.2024Scientific reports免费全文
  18. Identification of mitochondrial-related signature and molecular subtype for the prognosis of osteosarcoma.2023Aging免费全文
  19. Molecular characterization of cancer-intrinsic immune evasion genes indicates prognosis and tumour microenvironment infiltration in osteosarcoma.2023Aging免费全文
  20. Deubiquitinating enzyme USP10 promotes osteosarcoma metastasis and epithelial-mesenchymal transition by stabilizing YAP1.2023Cancer medicine免费全文
  21. Exploring the immune microenvironment of osteosarcoma through T cell exhaustion-associated gene expression: a study on prognosis prediction.2023Frontiers in immunology免费全文
  22. Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma.2022Biomolecules免费全文
  23. Hsp90 regulates the tumorigenic function of tyrosine protein kinase in osteosarcoma.2022Clinical and experimental pharmacology & physiology
  24. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma.2022Computational and mathematical methods in medicine免费全文
  25. Low GNG12 Expression Predicts Adverse Outcomes: A Potential Therapeutic Target for Osteosarcoma.2021Frontiers in immunology免费全文
  26. Revealing the link between macrophage in microenvironment of osteosarcoma and poor prognosis by utilizing the Integrated analysis.2021Journal of musculoskeletal & neuronal interactions免费全文
早期论文(2016–2020 年)6
  1. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1.2020Experimental cell research
  2. ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.2019Experimental cell research
  3. Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma.2017European journal of cancer care
  4. [Effect of ursolic acid on proliferation and apoptosis of human osteosarcoma cell line U2-OS].2017Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  5. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway.2016Biochemical and biophysical research communications
  6. High level of αB-crystallin contributes to the progression of osteosarcoma.2016Oncotarget

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南昌有 4 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文1
  1. Expression of DOG1 in peripheral blood cells of patients with gastrointestinal stromal tumor.2021Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study状态不明NCT05440357研究中心2022-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南昌有 4 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 5520242025: 222025

南昌有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    发布
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    发布
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层CAR-T 与细胞治疗干细胞移植
论文中的科室病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: A meta-analysis.2025Biomolecules & biomedicine免费全文
  2. METTL5 regulates SEPHS2-mediated selenoprotein synthesis to promote multiple myeloma survival and progression.2025Cell death & disease免费全文
  3. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.2024Cancer gene therapy免费全文
  4. lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts.2024International immunopharmacology
  5. Exosomal lncRNA NEAT1 Inhibits NK-Cell Activity to Promote Multiple Myeloma Cell Immune Escape via an EZH2/PBX1 Axis.2024Molecular cancer research : MCR
  6. The value of myocardial contraction fraction and long-axis strain to predict late gadolinium enhancement in multiple myeloma patients with secondary cardiac amyloidosis.2024Scientific reports免费全文
  7. A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma.2024Technology in cancer research & treatment免费全文
  8. Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis.2023International immunopharmacology
  9. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.2021BMC cancer免费全文
  10. Multiple myeloma with CD138 changed from positive to negative: A case report.2021Cytometry. Part B, Clinical cytometry
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  3. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.4%。

牵头论文
15
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 4420232024: 3320242025: 332025

南昌有 3 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 邀请入组
    A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
    分期
    III期
    开始
    2024-07
    发布
    登记号
    NCT07348575

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南昌大学第二附属医院南昌

  2. 正在招募
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    分期
    III期
    开始
    2025-09
    发布
    登记号
    NCT06973187

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、兰州、北京、南宁、南昌、南通、哈尔滨、大连、太原、宁波、徐州、成都、武汉、沈阳、泸州、温州、石家庄、福州、苏州、西宁、西安、郑州、长春、长沙

  3. 正在招募
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    分期
    未注明
    开始
    2025-09
    发布
    登记号
    NCT07200375

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、南昌、哈尔滨、天津、宁波、广州、成都、武汉、济南、温州、烟台、西安、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科肿瘤内科影像/核医学科普外/肝胆胰外科
牵头的论文15
  1. Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to lymphoma.2025Critical reviews in oncology/hematology
  2. An analysis of the relationship of triglyceride glucose index with diffuse large B-cell lymphoma prognosis: a retrospective study.2025Frontiers in endocrinology免费全文
  3. Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches.2025International immunopharmacology
  4. The role of the gut microbiota in infectious complications during immunochemotherapy for diffuse large B-cell lymphoma.2024BMC cancer免费全文
  5. Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  6. Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.2024Frontiers in immunology免费全文
  7. Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma.2023Cell death & disease免费全文
  8. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma.2023Frontiers in immunology免费全文
  9. Prediction of sentinel lymph node metastasis in breast cancer by using deep learning radiomics based on ultrasound images.2023Medicine免费全文
  10. Identification of the shared gene signatures and molecular pathways in systemic lupus erythematosus and diffuse large B-cell lymphoma.2023The journal of gene medicine
  11. Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma.2022Frontiers in immunology免费全文
  12. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.2022Journal of Zhejiang University. Science. B免费全文
  13. Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.2022Oxidative medicine and cellular longevity免费全文
  14. Simple cholecystectomy is an adequate treatment for grade I T1bN0M0 gallbladder carcinoma: Evidence from 528 patients.2022World journal of gastroenterology免费全文
  15. CBL aggravates Ang II-induced cardiac hypertrophy via the VHL/HIF-1α pathway.2021Experimental cell research
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma邀请入组NCT07348575牵头方III期2024-07 启动
  2. An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma正在招募NCT07200375研究中心2025-09 启动
  3. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma正在招募NCT06973187研究中心III期2025-09 启动
  4. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors进行中,不再招募NCT06970743研究中心III期2025-05 启动
  5. Evaluating Different Doses of Orelabrutinib in MCL已完成NCT05978739研究中心II期2023-08 启动
  6. Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients进行中,不再招募NCT05651178研究中心早期I期2022-08 启动
  7. AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)已完成NCT06511869研究中心II期2022-03 启动
  8. Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)进行中,不再招募NCT04666038研究中心III期2021-03 启动
  9. Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.状态不明NCT03720457研究中心I期2018-11 启动
  10. A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)已终止NCT01287741研究中心III期2011-07 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南昌有 2 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南昌有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

南昌有 2 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流中风与出血
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南昌有 1 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
研究主题遗传学(ATP7B)治疗(螯合剂、锌剂)诊断与铜代谢检测
论文中的科室消化/肝病科肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.4%。

牵头论文
21
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 7720232024: 3320242025: 662025

南昌有 3 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
    分期
    不分期
    开始
    2026-05
    发布
    登记号
    NCT07587099

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心乌鲁木齐、北京、南昌、哈尔滨、济南、海口、聊城、青岛

  2. 即将招募
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    分期
    不分期
    开始
    2021-09
    发布
    登记号
    NCT04995159

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 67 家列出的医院为研究中心上海、中山、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、天津、太原、广州、徐州、昆明、杭州、武汉、汕头、洛阳、济南、海口、淄博、淮安、湛江、烟台、珠海、石家庄、蚌埠、西安、贵阳、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文21
  1. Developing and validation of the Sexual Fear Scale in Chinese patients with coronary heart disease.2025BMC cardiovascular disorders免费全文
  2. Randomized Controlled Trial Assessing the Efficacy and Safety of a Liposomal Carrier for Low-Dose Dual Antiplatelet Therapy (Clopidogrel and Aspirin) in Coronary Heart Disease Patients.2025Clinical therapeuticsRCT
  3. Relationship between blood pressure and adverse clinical events in patients undergoing percutaneous coronary intervention (PCI): a retrospective analysis.2025European journal of medical research免费全文
  4. L-shaped association between ankle-brachial index and coronary heart disease in Chinese adults with hypertension.2025European journal of medical research免费全文
  5. Validation of a Prediction Model From Quantitative Coronary Angiography to Detect Ischaemic Lesions as Evaluated by Invasive Fractional Flow Reserve.2025Heart, lung & circulation
  6. A deep learning model could screen for coronary heart disease from a "pseudo-normal" electrocardiogram.2025Medicine免费全文
  7. Systemic immune-inflammation index and in-stent restenosis in patients with acute coronary syndrome: a single-center retrospective study.2024European journal of medical research免费全文
  8. Association between body shape index and coronary heart disease in individuals over 20 years old with obese.2024Journal of health, population, and nutrition免费全文
  9. Predictive value of the triglyceride-glucose index for short- and long-term all-cause mortality in patients with critical coronary artery disease: a cohort study from the MIMIC-IV database.2024Lipids in health and disease免费全文
  10. Coronary artery spasm treated with intracoronary bioresorbable scaffold implantation under the guidance of treadmill test and optical coherence tomography: A case report.2023Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc免费全文
  11. Relationship between Dietary Decanoic Acid and Coronary Artery Disease: A Population-Based Cross-Sectional Study.2023Nutrients免费全文
  12. Coronary CT Angiography-based Morphologic Index for Predicting Hemodynamically Significant Coronary Stenosis.2023Radiology. Cardiothoracic imaging免费全文
  13. Influence of sodium thiosulfate on coronary artery calcification of patients on dialysis: a meta-analysis.2023Renal failure免费全文
  14. Causal effect of gallstone disease on the risk of coronary heart disease or acute myocardial infarction: a Mendelian randomization study.2023Scientific reports免费全文
  15. Association study of urinary iodine concentrations and coronary artery disease among adults in the USA: National Health and Nutrition Examination Survey 2003-2018.2023The British journal of nutrition免费全文
  16. Sleep Patterns Modify the Association between Vitamin D Status and Coronary Heart Disease: Results from NHANES 2005-2008.2023The Journal of nutrition
  17. Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: "Real-world" evidence.2022Clinical cardiology免费全文
  18. Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.2022Clinical rheumatology
  19. Sex differences in assessing stenosis severity between physician visual assessment and quantitative coronary angiography.2022International journal of cardiology
  20. Lipid metabolism patterns and relevant clinical and molecular features of coronary artery disease patients: an integrated bioinformatic analysis.2022Lipids in health and disease免费全文
  21. The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis.2021European journal of clinical pharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Glycemic Variability, Gut Microbiota, and Prognosis in T2DM With ACS状态不明NCT06573060牵头方2023-07 启动
  2. Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)正在招募NCT07587099研究中心不分期2026-05 启动
  3. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System即将招募NCT04995159研究中心不分期2021-09 启动
  4. FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease进行中,不再招募NCT06218485研究中心不分期2024-03 启动
  5. Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting已完成NCT02565615研究中心2016-06 启动
  6. Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)状态不明NCT02448524研究中心III期2015-07 启动
  7. A Trial to Evaluate Efficacy of Heart-protecting Musk Pill状态不明NCT01897805研究中心IV期2011-07 启动
  8. Acarbose Cardiovascular Evaluation Trial已完成NCT00829660研究中心IV期2009-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.4%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 2220232024: 2220242025: 332025

南昌有 4 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文11
  1. Special type B interrupted aortic arch diagnosis by angiography in an adult patient: a case report.2025Cardiology in the young
  2. Extreme compensatory dilatation of the splanchnic artery caused by congenital coarctation of the abdominal aorta: a case report.2025Journal of medical case reports免费全文
  3. Topological Distribution of KCNH2 Variants and Genotype-Phenotype Relationship in Patients With Long QT Syndrome.2025Pacing and clinical electrophysiology : PACE
  4. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients.2024Cardiovascular drugs and therapy
  5. Lactobacillus plantarum 24-7 improves postoperative bloating and hard stools by modulating intestinal microbiota in patients with congenital heart disease: a randomized controlled trial.2024Food & functionRCT
  6. Aorto-ventricular tunnel with three orifices: a unique case report diagnosed by transthoracic echocardiography.2023Cardiovascular ultrasound免费全文
  7. Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry.2023The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  8. Long-segmental middle aortic coarctation: a rare case first diagnosed by transthoracic echocardiography.2022BMC cardiovascular disorders免费全文
  9. Diagnosis of fetal congenitally unguarded tricuspid valve orifice by echocardiography.2022Echocardiography (Mount Kisco, N.Y.)
  10. Abrupt formation of intracardiac thrombus during patent foramen ovale closure by three-dimensional transesophageal echocardiography.2022Echocardiography (Mount Kisco, N.Y.)
  11. A 15-Year-Old Adolescent With Obstructive Shock and Emerging Thrombus.2021JACC. Cardiovascular interventions
中文论文(未计入)1
  1. [Pharmacogenetic exploration of genes associated with cardiac ion channel disease].2025Zhonghua xin xue guan bing za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南昌有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis即将招募NCT07451665研究中心IV期2026-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南昌有 4 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
牵头的论文1
  1. Follicular helper T cells and fibrotic diseases.2025Cellular immunology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南昌有 4 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

南昌有 1 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.4%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 3320232024: 1120242025: 442025

南昌有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文10
  1. Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.2025BMC nephrology免费全文
  2. IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristics.2025Clinical and experimental rheumatology
  3. Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway.2025EMBO molecular medicine免费全文
  4. Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton.2025International immunopharmacology
  5. The efficacy of rituximab in the treatment of IgA vasculitis nephritis.2024Clinical and experimental medicine免费全文
  6. The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis.2023Frontiers in immunology免费全文
  7. New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination.2023QJM : monthly journal of the Association of Physicians
  8. New-onset IgA nephropathy following COVID-19 vaccination.2023QJM : monthly journal of the Association of Physicians免费全文
  9. Effectiveness and safety of tacrolimus treatment for IgA nephropathy: A prospective cohort study.2022Medicina clinica
  10. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy.2021BMC nephrology免费全文
早期论文(2016–2020 年)2
  1. Differential expression of urinary exosomal microRNAs in IgA nephropathy.2018Journal of clinical laboratory analysis
  2. Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis.2018Kidney & blood pressure research
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南昌有 2 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南昌有 2 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    发布
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南昌有 1 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

南昌大学第二附属医院

Second Affiliated Hospital of Nanchang University

南昌

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Nanchang University Second Affiliated Hospital; Second Affiliated Hospital of Nanchang Medical College; second affiliated hospital of Nanchang university; Second Affiliated Hospital of Nanchang University Nanchang; No.2 Affiliated Hospital of Nanchang University

提出更正下载数据